Â鶹ӳ»­

Researchers at Â鶹ӳ»­ MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results published today in Nature Cancer, the new approach combined the benefits of more well-known antibody-drug conjugates (ADCs) with those of immunotherapies.

ADCs have emerged as a breakthrough in recent years due to their...